New Medication for High Cholesterol Not Cost-Effective
A new study in JAMA evaluated the cost-effectiveness of PCSK9 inhibitors and how increased use might affect the U.S. healthcare system.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.